Healthcare, one of the largest and most complex sectors, is comprised of a broad range of companies that sell medical products and services. The healthcare sector includes companies that sell drugs, medical devices, and insurance, as well as hospitals and healthcare providers.
Some of the largest healthcare companies in the world include UnitedHealth Group Inc. (NYSE: UNH), Pfizer Inc. (NYSE: PFE), and Abbvie Inc. (NYSE: ABBV). These companies are currently sitting above or close to their all-time-high.
There is still plenty of value in the space, but you must know where to look. Here is a company that checks all the boxes:
- Uplisted to NASDAQ from the OTCQB
- Total addressable market $4.8 billion with 5% annual growth
- Has a product that treats the affliction, not just the symptoms
- Miminum FDA Risk
- Scalable manufacturing
- Seasoned Staff
- Acquisiton & sales minded
- Patent Protection
Veterinary surgical sutures market accounted for a market value of US$ 264.13 million in 2019 and projected to grow at a CAGR of 6.7% during the forecast period from 2021 to 2029 as reported by Research and Markets.
Here is a company you need to look at if you want to capitalize on growth in the space.
PetVivo Holdings Inc. (NASDAQ: PETV) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals.
PetVivo, Inc. (NASDAQ: PETV), is the producer of “Kush”, which is a veterinarian-administered intraarticular injection for the treatment of osteoarthritis and other lameness issues in dogs and horses that is intended to provide a lubricious cushion within the joint and between the bones to reinforce cartilage. KUSH is scheduled for expanded commercial sales and the development of its proprietary mucoadhesive active agent delivery products.
Kush is made from natural materials (collagen elastin and heparin), typically lasts for 12 months or longer and can be repeated annually or as needed.
PetVivo is expected to expand commercial production and availability of Kush in Q1 2021, in the $4.8 billion dog and horse therapeutics market.
Motley Fool recently discussed two veterinary companies. They named Trupanion (NASDAQ: TRUP) as a stock that could turn a $25,000.00 investment into $1 million or more, and it also recently reported that Idexx Laboratories (NASDAQ: IDXX), is up almost 34% year to date and at an all-time high after the acquisition of ezyVet in June.
The sector is hot and PetVivo Holdings (NASDAQ: PETV) could just be that horse waiting get out of the gate.
Petvivo (NASDAQ: PETV) recently announced that the United States Patent and Trademark Office (USPTO) has issued a patent related to the Company’s proprietary encapsulated or coated stent systems. The company currently has 16 products in its pipeline, and a portfolio of 19 patents that protect them.
PetVivo Holdings, Inc. made a name for itself when a successful Kush case study came to light when Fender Bender, a racehorse suffering from osteoarthritis, was put up for sale and claimed for $3,000.00 and the new owner treated him with PetVivo’s Kush. Fender Bender won at Canterbury Park on August 4, 2020.
Any of the majors in the space could benefit from PetVivo’s proprietary assets, but while PetVivo may or may not be on a “seeking to be acquired” path, it is on an aggressive growth / valuation path.
In June of 2018, Dr. Turner was added to PetVivo’s advisory board.
In the presentation, Dr. Turner recalls a horse with an injured meniscus that was no longer responsive to any other therapy. As a last resort, he injected the horse with Kush, and at his follow up appointment two weeks later, Dr. Turner was so amazed at the results that he thought the owner switched horses on him.
Advances in veterinary health care are providing meaningful improvement in our pets’ lives. There are ongoing innovations in veterinary treatments, preventative medications, diagnostics, screening tools, imaging (MRIs and other scans), wellness products and therapies supported by owners willing to pay for these treatments.
As an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals, PetVivo Holdings, Inc. is leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
On August 10, 2021, The common shares and warrants have been approved to list on the Nasdaq Capital Market under the symbols “PETV” and “PETVW” respectively, and are expected to begin trading on Wednesday, August 11, 2021.
If you are looking for value in the space in the form of a company with proprietary technology that could either realize exponential growth, or be acquired by a major who would rather buy the wheel then reinvent it, look no further than PetVivo Holdings, Inc. (NASDAQ: PETV)2020